| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Unité de Recherches sur lEndocrinologie du Développement (Institut National de la Santé et de la Recherche Médicale) (C.B., J.-Y.P., N.J., N.D.), 92140 Clamart, France; and Biogen, Inc. (H.V.V., C.E., B.P., A.R.R., R.L.C.), Cambridge, Massachusetts 02142
Address all correspondence and requests for reprints to: Dr. Richard L. Cate, Biogen, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142. E-mail: Richard.Cate{at}biogenidec.com.
Anti-Müllerian hormone (AMH), a TGF-ß family member, determines whether an individual develops a uterus and Fallopian tubes. Mutations in the AMH gene lead to persistent Müllerian duct syndrome in males. The wild-type human AMH protein is synthesized as a disulfide-linked dimer of two identical 70-kDa polypeptides, which undergoes proteolytic processing to generate a 110-kDa N-terminal dimer and a bioactive 25-kDa TGF-ß-like C-terminal dimer. We have studied the biosynthesis and secretion of wild-type AMH and of seven persistent Müllerian duct syndrome proteins, containing mutations in either the N- or C-terminal domain. Mutant proteins lacking the C-terminal domain are secreted more rapidly than full-length AMH, whereas single amino acid changes in both domains can have profound effects on protein stability and folding. The addition of a cysteine in an N-terminal domain mutant, R194C, prevents proper folding, whereas the elimination of the cysteine involved in forming the interchain disulfide bond, in a C-terminal domain mutant, C525Y, leads to a truncation at the C terminus. A molecular model of the AMH C-terminal domain provides insights into how some mutations could affect biosynthesis and function.
This article has been cited by other articles:
![]() |
X. Wu, S. Wan, S. Pujar, M. E. Haskins, D. H. Schlafer, M. M. Lee, and V. N. Meyers-Wallen A Single Base Pair Mutation Encoding a Premature Stop Codon in the MIS Type II Receptor Is Responsible for Canine Persistent Mullerian Duct Syndrome J Androl, January 1, 2009; 30(1): 46 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Catteau-Jonard, S. P. Jamin, A. Leclerc, J. Gonzales, D. Dewailly, and N. di Clemente Anti-Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4456 - 4461. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Kevenaar, J. S. E. Laven, S. L. Fong, A. G. Uitterlinden, F. H. de Jong, A. P. N. Themmen, and J. A. Visser A Functional Anti-Mullerian Hormone Gene Polymorphism Is Associated with Follicle Number and Androgen Levels in Polycystic Ovary Syndrome Patients J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1310 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Goglia, C. Toncini, M. Giusti, C. Gastaldi, C. Ambruosi, S. Sola, J.-L. Ravetti, G. Carmignani, F. Minuto, and D. Ferone A Unique Association of Clinical "Persistent Mullerian Duct Syndrome" and Syringoid Carcinoma of the Perineal-Scrotal Skin: A Consequence of Urologic Surgery? J Androl, January 1, 2008; 29(1): 15 - 19. [Full Text] [PDF] |
||||
![]() |
N. Josso, C. Belville, N. di Clemente, and J.-Y. Picard AMH and AMH receptor defects in persistent Mullerian duct syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 351 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. X. Liao, R. K. Moore, and S. Shimasaki Functional and Molecular Characterization of Naturally Occurring Mutations in the Oocyte-secreted Factors Bone Morphogenetic Protein-15 and Growth and Differentiation Factor-9 J. Biol. Chem., April 23, 2004; 279(17): 17391 - 17396. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |